HOME >> BIOLOGY >> NEWS
JCI table of contents -- April 5, 2007

EDITOR'S PICK: Tumors stopped from spreading to new sites

For several types of cancer, persistently high levels of the soluble factor TGF-beta in the blood after surgery, chemotherapy, or radiation therapy correlate with increased risk of early metastasis and a poor prognosis. Using a mouse model of breast cancer, researchers from Vanderbilt University have now generated evidence to suggest that treatment with TGF-beta inhibitors might help such patients.

In the study, which appears online on April 5 in advance of publication in the May print issue of the Journal of Clinical Investigation, Carlos Arteaga and colleagues show that treating mice with mammary tumors with either radiation or the chemotherapeutic drug doxorubicin increased the level of TGF-beta in their blood, the number of cancer cells in their blood, and the development of lung metastases. Treatment with an inhibitor of TGF-beta blocked the increased lung metastases. Furthermore, mice whose tumors did not express the receptor for TGF-beta did not develop increased incidence of lung metastases after treatment with radiation, indicating that TGF-beta affects the cancer cells directly, enhancing their metastatic function. This study has important clinical implications as it suggests that monitoring TGF-beta levels after primary therapy might indicate the patients most at risk of developing tumor metastases and that treatment with TGF-beta inhibitors might be of clinical benefit to these individuals.

TITLE: Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression

AUTHOR CONTACT:
Carlos L. Arteaga
Vanderbilt University School of Medicine, Nashville, Tennessee, USA
Phone: (615) 936-3524; Fax: (615) 936-1790; E-mail: carlos.arteaga@vanderbilt.edu.

View the PDF of this article at:

Contact: Karen Honey
press_releases@the-jci.org
215-573-1850
Journal of Clinical Investigation
5-Apr-2007


Page: 1 2 3 4 5 6

Related biology news :

1. Antioxidant overload may underlie a heritable human disease
2. JCI table of contents: Aug. 9, 2007
3. JCI table of contents: August 1, 2007
4. US Department of Defense awards $1.6 million for implantable biochip research
5. More fish oil, less vegetable oil, better for your health
6. JCI table of contents -- July 26, 2007
7. JCI table of contents: July 19, 2007
8. JCI table of contents: July 12, 2007
9. JCI table of contents: June 21, 2007
10. JCI table of contents: June 14, 2007
11. Food safety begins as vegetables grow

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/13/2017)... SAN FRANCISCO , Feb. 13, 2017 /PRNewswire/ ... a centralized platform that is designed to enhance ... the latest release in the RSA Fraud & ... to enable organizations to leverage additional insights from ... anti-fraud tools to better protect their customers from ...
(Date:2/9/2017)... , Feb. 9, 2017 The biomass ... analysis of the biomass boiler market globally in terms ... of biomass boilers. The market for biomass boilers has ... type, end-user, application, and country/region. The market based on ... & forest residues, biogas & energy crops, urban residues, ...
(Date:2/8/2017)... Report Highlights ... The global synthetic-biology market reached nearly $3.9 ... growing at a compound annual growth rate (CAGR) of 24.0% ... global markets for synthetic biology. - Analyses of global market ... of compound annual growth rates (CAGRs) through 2021. - Coverage ...
Breaking Biology News(10 mins):
(Date:2/23/2017)... , Feb. 23, 2017  In Atlanta, it seems everyone ... and culture intertwine to create an expressive and dynamic community ... this energy and contribute to it. With ... Hair Fairies seeks to carry on that tradition with ... Atlanta salon is the newest of 13 ...
(Date:2/23/2017)... INDIANAPOLIS, Ind. (PRWEB) , ... February 23, 2017 ... ... Commercialization Award during the 12th annual Inventors Recognition Reception at Purdue Research ... annually to a faculty member in recognition of outstanding contributions to, and success ...
(Date:2/23/2017)... and SAN FRANCISCO , ... privately-held regenerative medicine company, and Beyond Type 1, a ... type 1 diabetes, today announced a grant from Beyond ... functional cure for type 1 and other insulin-requiring diabetes.  ... has been developing innovative stem cell-derived cell replacement therapies ...
(Date:2/22/2017)... Feb. 22, 2017  PrimeVax Immuno-Oncology, Inc. announced today ... at the Annual Biocom Global Life Science Partnering Conference.  ... 11:15 AM, at the Torrey Pines Lodge, in San ... organizers at Biocom who have chosen our company, amongst ... biotechnology companies, investors, and clinical researchers," said Mr. Chen. ...
Breaking Biology Technology:
Cached News: